SIRT6 agonist MDL-800 tested in 24-month-old mice: disc health and safety signals
In 24-month-old mice, systemic MDL-800, a small-molecule SIRT6 activator, was linked to healthier disc morphology, better cell viability and lower degeneration scores; the abstract reports good systemic tolerance but also mild hyperalgesia and small vertebral changes. [1]
Automatic summary · not editorially reviewed
The key findings
The study tested long-term systemic MDL-800, a small-molecule SIRT6 activator, in 24-month-old mice. [1]
After MDL-800, discs showed healthy morphology, enhanced cell viability and lower degeneration scores, with reduced senescence markers. [1]
Treated mice showed good systemic tolerance but also mild hyperalgesia and a small decrease in vertebral structural parameters, without vertebral fractures. [1]
The source at a glance
- Study type / format
- Preclinical mouse study (abstract)
- Population / context
- 24-month-old mice
- Summary based on
- Study abstract
- Original publication
- October 1, 2026
SIRT6 activation tested in aged mouse discs
The abstract frames aging as a key risk factor for intervertebral disc degeneration, a major contributor to chronic low back pain. Earlier loss-of-function studies had shown that SIRT6, a nuclear NAD-dependent deacetylase, maintains disc health. The authors therefore asked whether long-term SIRT6 activation through systemic delivery of the small-molecule agonist MDL-800 improves disc health in 24-month-old mice. This is a preclinical mouse study; the abstract does not report sample sizes, treatment duration or a control group description.
Supporting source [1]
Disc and epigenetic changes after MDL-800 in mice
The abstract reports healthy disc morphology, enhanced cell viability and lower degeneration scores after MDL-800 treatment. SIRT6 activation decreased H3K9ac levels, improved extracellular matrix quality and reduced senescence, indicated by lower p21, IL-6, TGF-β and CCL2. Analyses of tissue RNA and chromatin accessibility showed altered epigenetic marks (decreased H3K9ac, H3K36me3 and H3K79me2) and transcriptomic landscapes. MDL-800 increased autophagy without affecting disc cellular bioenergetics. These are associations in mice, not evidence of a human lifespan or clinical benefit.
Supporting source [1]
Systemic tolerance and vertebral signals in treated mice
Plasma metabolomics, single-cell RNA sequencing of lymphoid tissues (bone marrow and spleen) and cytokine profiling showed good systemic tolerance of the treatment. The authors also noted a small decrease in vertebral structural parameters and mild hyperalgesia in treated cohorts, but no vertebral fractures; broader motor function and behavior remained unaffected, and they raised no safety concerns. The abstract does not give effect sizes, statistics or a full safety assessment.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a preclinical mouse study, and the abstract does not report sample sizes, treatment duration, control groups, effect sizes or statistics. Findings in mice do not establish human benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ramteke P, Watson B, Jagannath S, Bell SE, Toci M, Ottone O, Wu Q, Abinader O, Mitra R, Collins JA, Barve RA, Risbud MV. · europepmc.org · October 1, 2026